| MBL (at the end of treatment) | ||||
|---|---|---|---|---|
| Study | Comparison | N | Results | Comment/conclusions |
| Fraser 2011 | E2V/DNG versus placebo | 231 (149 in COCP group and 82 in placebo group overall; 136 and 76, respectively who had confirmed HMB) | Mean (SD) E2V/DNG: 46.7 (72.7) (N = 104) Placebo: 168.6 (112.6) (N = 60) |
No statistical test reported |
| Jensen 2011 | E2V/DNG versus placebo | 190 (120 in COCP group and 70 in placebo group overall); 91 and 60, respectively who had confirmed HMB) | Mean (SD) E2V/DNG: 47.5 (58.5) (N = 68) Placebo: 116.9 (77.5) (N = 42) |
No statistical test reported |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.